PARP inhibitors as first-line maintenance therapy in ovarian cancer

PFS increase but no OS increase for niraparib in advanced ovarian cancerПодробнее

Ovarian Cancer & PARP Inhibitors with Dr. B.S. Ankit Nehra | Oncology Perspective 2024Подробнее

Precision Medicine in Oncology: Ep.9 DEBATE - Is PARP inhibitor maintenance therapy in first-line...Подробнее

Precision Medicine in Oncology: Ep.11. Selection and use of PARP inhibitors for first-line mainte...Подробнее

Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ov...Подробнее

Advancing Therapeutic Paradigms for Ovarian Cancer in The Era of PARP Inhibitors: A Guide for The...Подробнее

Clinical Investigators Provide Perspectives on Cases of Patients with Ovarian and Endometrial CancerПодробнее

Clinical Advances in Ovarian Cancer: Exploring the Expanding Role of PARP Inhibitors in the Treat...Подробнее

Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ov...Подробнее

New First-Line Treatment for Stage III-IV High Grade Ovarian Serous Cancers (HGOSC)Подробнее

Hall A - Day 2 - AstraZeneca Symposium 2Подробнее

What’s New with PARP Inhibitors and Ovarian Cancer?Подробнее

Ovarian Cancer and Tumor Treating Fields | Oncology Today with Dr Neil Love — Role of PARP Inhibi...Подробнее

Ovarian Cancer | Cases from the Community: Investigators Discuss Available Research Guiding the C...Подробнее

PARP Inhibitors in the Management of Ovarian Cancer GuidelineПодробнее

Episode 227: Biomarker Testing, PARP Inhibitors, and Oral Adherence During Ovarian Cancer Mainten...Подробнее

PARP Inhibitors: 2023 UpdatesПодробнее

PARP inhibitor treatment in non-BRCA mutant high-grade serous ovarian cancer – Dr. Nicola HannawayПодробнее

Ovarian Cancer | Breakfast with the Investigators: Ovarian CancerПодробнее

PARP Inhibitors in the Management of Ovarian Cancer Rapid Recommendation UpdateПодробнее